echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis Q1: Entresto submits US$789 million US listing application for tislelizumab at the end of the year

    Novartis Q1: Entresto submits US$789 million US listing application for tislelizumab at the end of the year

    • Last Update: 2021-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 27, Novartis announced the results for the first quarter of 2021.


    Novartis' current business is divided into two main lines: innovative drugs and generic drugs.


    From the perspective of specific products, the rheumatoid immune disease treatment drug Cosentyx (skucilumab) and the new heart failure drug Entresto (sacquatril valsartan) contributed a total of 1.


    Zolgensma, a gene therapy for spinal muscular atrophy, has benefited from geographical penetration and is currently in an outbreak, with a double-digit growth rate of 88% reaching US$319 million.


    In addition, Novartis mentioned in its financial report the PD-1 tislelizumab introduced from BeiGene on January 12.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.